Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novavax's other current liabilities for the quarter that ended in Mar. 2026 was MXN2,388 Mil.
Novavax's quarterly other current liabilities
increased
from Sep. 2025 (MXN3,481 Mil) to Dec. 2025 (MXN4,261 Mil) but then
declined
from Dec. 2025 (MXN4,261 Mil) to Mar. 2026 (MXN2,388 Mil).
Novavax's annual other current liabilities
declined
from Dec. 2023 (MXN15,571 Mil) to Dec. 2024 (MXN5,838 Mil) and
declined
from Dec. 2024 (MXN5,838 Mil) to Dec. 2025 (MXN4,261 Mil).
The historical data trend for Novavax's Other Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.
What does a Other Current Liabilities of MXN2,388 Mil mean?
Novavax (MEX:NVAX) has a Other Current Liabilities of MXN2,388 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Novavax.
Is Novavax's Other Current Liabilities too high?
Novavax's current Other Current Liabilities is MXN2,388 Mil. Overall, Novavax has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Other Current Liabilities compare to JBIO and AVLN?
Novavax's Other Current Liabilities of MXN2,388 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Novavax. Novavax's current Other Current Liabilities is MXN2,388 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (MEX:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN64.32, compared to a current price of MXN132.00 — trading 105.2% above its estimated fair value. The current Other Current Liabilities is MXN2,388 Mil. Novavax's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Novavax (MEX:NVAX), the current Other Current Liabilities is MXN2,388 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novavax (MEX:NVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Novavax stock appears to be overvalued.
The current stock price of MXN132.00 is trading 105.2% above its estimated GF Value™ of MXN64.32.
GuruFocus considers Novavax to be Significantly Overvalued.
Key valuation signals for MEX:NVAX:
Other Current Liabilities: MXN2,388 Mil
GF Value™: MXN64.32 vs. price of MXN132.00 (105.2% above fair value)
No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
42GF Score
Get the complete analysis for MEX:NVAX
Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVAX has been successfully added to your 
